Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Completed · Phase 2 · Has a placebo group

Conditions studied: Friedreich Ataxia

In brief

The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity. This study will also evaluate the efficacy of TAK-831 versus placebo on activities of daily living (ADL) and other secondary assessments.

Key facts

Study ID

NCT03214588

Run by

Neurocrine Biosciences

People needed

67

Starts

2017-11-08

Expected to finish

2018-12-27

Last updated by the study team

2021-06-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Ataxia Center — Los Angeles, California, United States
• University of Florida Center for Movement Disorders — Gainesville, Florida, United States
• USF College of Medicine — Tampa, Florida, United States
• University of Iowa Children's Hospital — Iowa City, Iowa, United States
• Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.